Giredestrant
WO42312
Phase 2 small_molecule active
Quick answer
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer is a Phase 2 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active